PYREXIA is the #9 most commonly reported adverse reaction for TACROLIMUS, manufactured by Astellas Pharma US, Inc.. There are 4,738 FDA adverse event reports linking TACROLIMUS to PYREXIA. This represents approximately 2.1% of all 222,557 adverse event reports for this drug.
TACROLIMUS has an overall safety score of 90 out of 100. Patients taking TACROLIMUS who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
PYREXIA4,738 of 222,557 reports
PYREXIA is a less commonly reported adverse event for TACROLIMUS, but still significant enough to appear in the safety profile.
Other Side Effects of TACROLIMUS
In addition to pyrexia, the following adverse reactions have been reported for TACROLIMUS:
PYREXIA has been reported as an adverse event in 4,738 FDA reports for TACROLIMUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is PYREXIA with TACROLIMUS?
PYREXIA accounts for approximately 2.1% of all adverse event reports for TACROLIMUS, making it a notable side effect.
What should I do if I experience PYREXIA while taking TACROLIMUS?
If you experience pyrexia while taking TACROLIMUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.